GlassScriptPhysician profile
Asma Aziz
NPI 1922594456
$4,482.82
in general payments reported to CMS, 2019-2025
27 companies · $81.71 in 2025
The $81.71 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $295 · 2022: $1,786 · 2023: $1,225 · 2024: $1,096 · 2025: $81.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.55 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $956.49 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $458.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $353.22 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $328.01 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.29 | 2021-2023 | Jardiance, Tradjenta, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $283.42 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Astellas Pharma US INC | $276.63 | 2021-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $223.76 | 2021-2024 | |
| Amgen INC. | $223.50 | 2022-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $184.89 | 2021-2022 | |
| Glaxosmithkline, LLC. | $151.59 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $144.03 | 2022 | |
| Novartis Pharmaceuticals Corporation | $137.51 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $108.57 | 2021-2023 | Steglatro, Belsomra |
| Exact Sciences Corporation | $74.78 | 2023-2025 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $48.23 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $37.15 | 2024 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.22 | 2023-2024 | Caplyta |
| Dexcom, INC. | $32.16 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $27.03 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.21 | 2022 | |
| Orthofix Medical, INC. | $15.22 | 2024 | Physio-Stim |
| Edwards Lifesciences Corporation | $15.00 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2022 | |
| Genentech USA, INC. | $13.09 | 2022 | |
| Almatica Pharma LLC | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.